Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) headquartered in Cambridge, will host a conference call for the investment community to discuss the 3Q20 financial results on 9th November 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.infi.com
Earnings Expectation
Infinity Pharmaceuticals, Inc. drug discovery and development firm, is expected to report third quarter earnings results, after market close, on Monday 9th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.16 per share from revenue of $ 0.16 million. Looking ahead, the full year loss are expected at $ 0.64 per share on the revenues of $ 2.19 million.
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc.
